Age (yr) | | | |

Median (range) | 66 (39–85) | 66.5 (38–82) | 66.5 (38–81) |

*P* value^{c} | | 0.493 | 0.866 |

Gender | | | |

Male | 34 (19.7%) | 16 (20.0%) | 12 (20.7%) |

Female | 139 (80.4%) | 64 (80.0%) | 46 (79.3%) |

*P* value^{d} | | 0.949 | 0.864 |

Smoking status | | | |

Never | 24 (13.9%) | 6 (7.5%) | 4 (6.9%) |

Former | 100 (57.8%) | 37 (46.3%) | 26 (44.8%) |

Current | 49 (28.3%) | 37 (46.3%) | 28 (48.3%) |

*P* value^{d} | | 0.015 | 0.016 |

Treatment regimen | | | |

Placebo | 88 (50.9%) | 46 (57.5%) | 35 (60.3%) |

13 cRA | 85 (49.1%) | 34 (42.5%) | 23 (39.7%) |

*P* value^{d} | | 0.326 | 0.211 |

IGF-I ng/ml | | | |

Median (range) | 93.61 (17.19–352.33) | 134.85 (20.14–422.27) | 137.97 (20.14–422.27) |

*P* value^{c} | | 0.001 | 0.002 |

IGFBP-3 ng/ml | | | |

Median (range) | 2405.8 (256.8–6421.6) | 2969.6 (708.6–5538.6) | 2999.2 (708.6–5538.6) |

*P* value^{c} | | 0.019 | 0.004 |

IGF-I/IGFBP-3 molar ratio | | | |

Median (range) | 0.15 (0.02–0.83) | 0.17 (0.02–1.09) | 0.16 (0.02–1.09) |

*P* Value^{c} | | 0.044 | 0.224 |